Poland Aims to Increase Tax Rate for Banks
Written by Emily J. Thompson, Senior Investment Analyst
Source: WSJ
Polish Bank Stocks Decline: Polish bank stocks fell significantly following the finance ministry's announcement to raise corporate income tax rates for lenders.
Impact on Major Banks: Major banks like PKO Bank Polski, Bank Pekao, and Santander Bank Polska experienced substantial losses.
Market Reaction: The banking sub-index in Warsaw dropped by 8.7% during European midday trading on Friday.
Budgetary Goals: The government's move aims to strengthen the national budget amidst economic challenges.
Analyst Views on EBS
Wall Street analysts forecast EBS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EBS is 15.00 USD with a low forecast of 15.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 12.090
Low
15.00
Averages
15.00
High
15.00
Current: 12.090
Low
15.00
Averages
15.00
High
15.00
About EBS
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
